Scar Treatment Injectable Fillers Market Report 2026

The scar treatment injectable fillers market size has grown rapidly in recent years. It will grow from $0.43 billion in 2025 to $0.48 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to rising prevalence of acne and traumatic scars, increasing consumer awareness regarding aesthetic treatments, growing adoption of cosmetic dermatology procedures, expansion of dermatology clinic infrastructure, advancements in injectable filler formulation technologies.

The scar treatment injectable fillers market size is expected to see rapid growth in the next few years. It will grow to $0.75 billion by 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to increasing demand for personalized aesthetic treatments, growing development of regenerative injectable fillers, rising investments in advanced scar revision therapies, expanding use of minimally invasive cosmetic procedures, increasing preference for long acting collagen stimulating fillers. Major trends in the forecast period include increasing adoption of minimally invasive scar correction procedures, growing demand for long lasting injectable fillers for scar treatment, rising preference for collagen stimulating fillers in dermatology applications, expanding use of combination therapies for complex scar management, increasing focus on biocompatible and safe dermal filler formulations.

The increasing prevalence of acne and scar conditions is expected to drive the growth of the scar treatment injectable fillers market. Acne and scar conditions are dermatological disorders characterized by skin inflammation, lesions, and the development of permanent marks or indentations resulting from the skin’s healing process. The growing prevalence of these conditions is linked to factors such as hormonal fluctuations, stress, and environmental pollution, which contribute to a higher occurrence of skin disorders. As more people experience moderate to severe acne that may result in scarring, the demand for effective aesthetic treatments continues to rise. Injectable fillers provide a minimally invasive treatment option by restoring skin volume, enhancing texture, and minimizing the appearance of scars. For instance, in October 2024, according to a study published in Cureus, a Saudi Arabia-based research publication, the prevalence of acne vulgaris among adolescents and young adults in Al-Baha reached 70.2% in 2024, increasing from 64.5% in 2023. Therefore, the increasing prevalence of acne and scar conditions is driving the growth of the scar treatment injectable fillers market.

Leading companies operating in the scar treatment injectable filler market are emphasizing advancements in hyaluronic acid-based fillers, such as injectable hyaluronic acid dermal fillers, to improve facial volume, smooth wrinkles, contour facial features, and enhance skin hydration for a natural and rejuvenated appearance. Injectable hyaluronic acid dermal fillers are sterile, gel-based formulations primarily composed of hyaluronic acid, a naturally occurring polysaccharide in the human body. For instance, in February 2025, Evolus announced FDA approval of Evolysse Form and Evolysse Smooth, the first two products in the Evolysse collection of injectable hyaluronic acid (HA) gels developed for facial aesthetic enhancement. Evolysse Form and Evolysse Smooth utilize innovative Cold-X technology to maintain the natural structure of the HA molecule, delivering long-lasting and natural-looking results. Both products demonstrated safety, effectiveness, and versatility in more than 2,000 patients globally, enabling precise injections at various skin depths for wrinkle reduction, facial contouring, and volume restoration, making them suitable for non-surgical facial rejuvenation.

In February 2025, Crown Laboratories, Inc. acquired Revance Therapeutics, Inc. for $3.65 per share in cash through the completion of a merger agreement. Through this acquisition, Crown aims to strengthen its position in aesthetic injectables by integrating Revance’s DAXXIFY neuromodulator and RHA Collection of dermal fillers into its portfolio, thereby expanding its range of minimally invasive aesthetic treatment solutions. Revance Therapeutics, Inc. is a US-based biotechnology company engaged in the development of aesthetic injectable products.

Major companies operating in the scar treatment injectable fillers market are LG Chem Ltd., Merz Pharma GmbH & Co. KGaA, MTF Biologics Inc., Dongkook Pharmaceutical Co. Ltd., Lumines Aesthetics Inc., Medytox Inc., Croma‑Pharma GmbH, Anika Therapeutics Inc., Regenyal Laboratories S. r. l., Prollenium Medical Technologies Inc., Hyalual LLC, Hangzhou Singclean Medical Products Co. Ltd., Teoxane Laboratories SA, Bloomage BioTechnology Corporation Limited, Promoitalia Group S. p. A., GANA R&D Co. Ltd., BioXis Pharmaceuticals LLC, BNC Korea Co. Ltd., Inbiotec S. A., MiMedx Group Inc., Jetema Co. Ltd.

North America was the largest region in the scar treatment injectable fillers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scar treatment injectable fillers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the scar treatment injectable fillers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The scar treatment injectable fillers market consists of sales of hyaluronic acid-based fillers, collagen-based fillers, poly-L-lactic acid fillers, and calcium hydroxylapatite fillers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the products, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.